Alfenta - General Information
A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfenta is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.
Pharmacology of Alfenta
Alfenta is a synthetic opioid analgesic. Alfenta interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, alfentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Alfenta may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Alfenta depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.
Alfenta for patients
As with any medication that you take, you should notify your physician of any changes in your overall condition. Be sure to follow your physician's instructions regarding follow-up visits. Please notify any physician who treats you for a medical condition that you are taking bepridil, as well as any other medications.
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics. Postoperative respiratory depression may be enhanced or prolonged by these agents. In such cases of combined treatment, the dose of one or both agents should be reduced. Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
Cimetidine reduces the clearance of ALFENTA. Therefore smaller ALFENTA doses will be required with prolonged administration and the duration of action of ALFENTA my be extended.
Perioperative administration of drugs affecting hepatic blood flow or enzyme function may reduce plasma clearance and prolong recovery.
ALFENTA (alfentanil hydrochloride) is contraindicated in patients with known hypersensitivity to the drug or known intolerance to other opioid agonists.
Additional information about Alfenta
Alfenta Indication: For the management of postoperative pain and the maintenance of general anesthesia.
Mechanism Of Action: Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Alfenta's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Alfentanil
Synonyms: Alfentanilum [Inn-Latin]; Alfentanyl
Drug Category: Anesthetics; Narcotics; Analgesics; Opiate Agonists
Drug Type: Small Molecule; Illicit; Approved
Other Brand Names containing Alfentanil: Alfenta;
Absorption: Not Available
Toxicity (Overdose): Symptoms of overexposure include characteristic rigidity of the skeletal muscles, cardiac and respiratory depression, and narrowing of the pupils.
Protein Binding: 92%
Biotransformation: The liver is the major site of biotransformation.
Half Life: 90-111 minutes
Dosage Forms of Alfenta: Solution Intravenous
Chemical IUPAC Name: N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide
Chemical Formula: C21H32N6O3
Alfentanil on Wikipedia: https://en.wikipedia.org/wiki/Alfentanil
Organisms Affected: Humans and other mammals